TÁC DỤNG KHÔNG MONG MUỐN PHÁC ĐỒ ETOPOSIDE-CISPLATIN TRÊN BỆNH NHÂN UNG THƯ PHỔI THẦN KINH NỘI TIẾT TẾ BÀO LỚN GIAI ĐOẠN MUỘN

Abstract

Objective: Evaluating several adverse events of cisplatin plus etoposide chemotherapy for the treatment for recurrent/ metastatic pulmonary large cells neuroendocrine carcinoma patients ith at Vietnam National Cancer Hospital from 1/2018 to 10/2021. Patients and Methods: A retrospective study of 33 patients diagnosed of recurrent/ metastatic pulmonary large cells neuroendocrine carcinoma were treated with first-line cisplatin plus etoposide chemotherapy at Vietnam National Cancer Hospital from 1/2018 to 10/2021. Results: Common toxicities on hematology were leukopenia and neutropenia, mostly grades 1 and 2. Rates all grades of leukopenia and neutropenia were 72.7% and 78.7%, respectively. Indeed, rates of grades 3-4 leukopenia and neutropenia were 33.3% and 30.3%, respectively. All grades of anemia accounted for 51/5%, including 15.1% of grades 3-4. Thrombopenia was reported in 15.1% for grades 3 and 4. Toxicities on non-hematology were rarely observed in case of grades 3 and 4. There were 3 cases of grades 3-4 kidney toxicity, and no persistence of elevated creatinine. There were 2 patients presented with grade 3 peripheral neurotoxicity. The most common causes lead to treatment interuption was leukopenia, accounted for 66.7%. Other causes were vomiting, pneumotitis, elevated liver enzymes and creatinine. Conclusion: Cisplatin plus etoposide chemotherapy for recurrent/metastatic stages in large cell neuroendocrine lung carcinoma had a higher risk of leukopenia and netropenia with a rate of over 30%.